BPI-2361 is high effective self-developed KRAS inhibitor. KRAS gene is the most frequently mutated oncogene in human cancers, which is about 20-30% of human cancers. Based on its wide patient distribution, the potential market for KRAS is comparable to PD-1. The incidence of KRASG12C in ...